Idiopathic Pulmonary Fibrosis (IPF)
Patient Condition
The patient sought medical treatment due to progressive dyspnea for 2 years and aggravated dry cough for 3 months. Thoracic HRCT showed diffuse lattice shadows and honeycomb lung changes in both lungs, particularly in both lower lungs. Pulmonary function tests: FVC accounted for 58% of the predicted value, and DLCO accounted for 42% of the predicted value. Bronchoscopy ruled out other interstitial lung diseases. IPF (UIP type) was diagnosed with a GAP score of 5 (stage II). mMRC dyspnoea score of 3.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| diagnostic assessment | ||
| Baseline assessment and treatment initiation | ||
| Standardized treatment (months 1-6) | ||
| Standardized treatment (7-12 months) | ||
| Follow-up and maintenance treatment (Months 13-24) |
Treatment Outcome
| before | FVC accounted for 58% of predicted value, DLCO accounted for 42% of predicted value, 6MWD 320m, mMRC score 3, GAP score 5 (Phase II) |
|---|---|
| after | After 24 months of treatment, FVC accounted for 50% of the predicted value (annual rate of decline was approximately 3.5%, which was lower than 8-10% of natural disease), DLCO accounted for 36% of the predicted value, 6MWD was 330m, and mMRC score was 3. Disease progression is significantly delayed |
| highlight | After 24 months of standardized treatment with Nintedanib, the annual decline rate of FVC dropped from the expected 8-10% to 3.5%. The effect of delaying disease progression was significant and the patient's quality of life remained stable. |